CGTN: Super Virus – COVID-19: How We Got Here
11.6.2020 18:12:00 EEST | Business Wire | Press release
The novel coronavirus has so far claimed over 400,000 lives worldwide, according to John Hopkins University. No one knows how dangerous the virus really is and how long the pandemic will last.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200611005636/en/
Super Virus COVID-19 (Photo: Business Wire)
To present readers with a clear picture of how we got here, CGTN portrayed seven* hard-hit countries in an interactive Super Virus. These countries – China, South Korea, the U.S., Germany, France, Italy and the UK – all reported initial confirmed cases at an early stage of the outbreak and all have their relatively mature healthcare systems strained in the fight against it. But their different policy measures have resulted in varied outcomes.
While it’s far too early to draw simple conclusions, the policy measures taken in each country do require scrutiny. The interactive takes a comparative approach in visualizing when and how quickly these measures were enacted over the course of the pandemic. CGTN compiled and analyzed data in the realms of testing, which is crucial to early detection, preventive measures including economic shutdowns and cancellation of public gatherings, as well as the development of clinical methods and the ultimate panacea – an effective vaccine.
Actions taken by countries in regards to testing in the early days appear to have contributed to huge differences down the road. Italy started out with mass testing but then scaled back to only focus on patients who were symptomatic. As the outbreak worsened in Britain, it focused testing and medical resources on critically ill patients.
South Korea and the U.S. reported their first coronavirus cases at almost the same time. But their governments’ attitudes toward testing amid the outbreak couldn’t be more different.
A week after South Korea reported its first case, its health department gathered more than 20 pharmaceutical companies to secure a testing method for COVID-19 that was settled upon eight days later. But weeks after the coronavirus landed in the U.S., there continued to be frustration over shortcomings in diagnostic test distribution and flawed test kits. First there was an outcry over the red tape in getting COVID-19 testing kits approved, then came confusion over who could get a test.
As for travel restrictions, border controls of different types were adopted by many of the six countries. Measures ranged from health checks at the airport to travel warnings and restrictions to quarantining returning overseas travelers. A latecomer to border controls, China didn’t implement restrictions until the end of March when global cases had already exploded.
Such a policy came with extreme measures in certain countries. The Trump administration suspended immigration to the U.S. for 60 days in the name of protecting domestic workers as unemployment hit a record high amid the coronavirus. But this policy left numerous families and businesses reeling instead of boosting employment.
Early-stage border controls also contributed to one problem: Most Western countries neglected prevention and control within their borders.
Restrictions on the movement of peoples within national borders were implemented with varying degrees of effectiveness. Most of the six countries, for instance, adopted stay-at-home orders ahead of lockdowns, except China. In the early morning of January 23, over 20 days after the first known cluster of cases was reported, Wuhan launched a severe lockdown, barring all cars, trains, planes in and out, which lasted 76 days.
In Italy, where similar measures were taken in the country’s northern Lombardy and Veneto – that, combined, makes up 30 percent of the Italian economy, residents were subjected to mandatory home quarantines with all non-essential businesses closed. Meanwhile, some of the other countries like the U.S. and the UK skipped imposing mandatory quarantines in the early stages due to various reasons.
COVID-19 caught the whole world off guard, exposing how we are underprepared in the face of a pandemic of such a scale and scope. The virus has grievously overburdened even the world’s best healthcare systems, with all the seven countries suffering from a dearth of medical professionals and supplies. Doctors and nurses continue to face the danger of being infected, and the psychological burden that they may spread the disease to other patients, or lost their jobs when back from the frontline.
The coronavirus is also not an equal offender — it has disproportionately affected historically marginalized populations. Rates of infection and death from the coronavirus are higher for African and Native Americans, who are on average poorer than their white counterparts. When it comes to age, the elderly makes up a sizable portion of all deaths, due to complications from the coronavirus on top of other conditions. Indigenous peoples are also experiencing higher rates of infection than the national averages of the countries they reside in. In Europe, the Roma live in overcrowded shantytowns, making them particularly affected by the outbreak given the lack of sanitary living conditions.
While outbreaks continue in many of these countries with advanced medical development, the future doesn’t seem to be defined by doom and gloom. Since the outbreak began in January, hundreds of universities, pharmaceutical companies and international organizations have participated in some 320 trials looking into various treatments for COVID-19. Given how divisive COVID-19 has been, the immense scale of this endeavor calls for cooperation across nations, organizations and societies. While time is the best asset for a rapidly spreading pandemic, it is not too late to cultivate this spirit of cooperation.
* The mobile version of the interactive only focuses on six countries for optimal user experience.
Original article: https://news.cgtn.com/news/2020-06-09/Super-Virus-COVID-19-How-we-got-here--Ra9s4L7rBC/index.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200611005636/en/
Contact information
Jiang Simin
jiang.simin@cgtn.com
+86 18826553286
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boomi Recognized as a Leader in the 2026 Gartner® Magic Quadrant™ for API Management30.9.2026 18:30:00 EEST | Press release
Boomi, the data activation company for AI, today announced it has been recognized as a Leader in the 2026 Gartner® Magic Quadrant™ for API Management. We believe the recognition reflects Boomi’s sustained investment in Boomi API Management as the governance layer enterprises use to turn fragmented APIs into a trusted foundation for AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930240079/en/ Boomi Recognized as a Leader in the 2026 Gartner® Magic Quadrant™ for API Management Our Key Takeaways Boomi has been recognized as a Leader in the 2026 Gartner® Magic Quadrant™ for API Management. A complimentary copy of the report is available here. Boomi is also a Leader in the Gartner® Magic Quadrant™ for Integration Platform as a Service, where it has been named a Leader 12 consecutive times. Boomi API Management gives organizations one control plane for the full API lifecycle, with automatic discovery of APIs across distribu
Echodyne Awarded $250 Million JIATF-401 Counter-UAS Contract30.9.2026 18:00:00 EEST | Press release
Echodyne, the radar platform company, today announced an indefinite-delivery/indefinite-quantity (IDIQ) contract supporting the Joint Interagency Task Force 401’s (JIATF-401) Domestic Shield program. The agreement has a $250 million ceiling and an ordering period of up to 36 months, providing a path to acquire counter-unmanned aircraft system (C-UAS) capabilities for force protection, base defense and counter-drone operations in the United States and abroad. As part of the agreement, Echodyne’s advanced MESA radars will be available for procurement on JIATF-401’s C-UAS Marketplace for U.S. and Allied Nations. At the center of Echodyne’s radar portfolio is MESA, its software-defined metamaterials electronically scanned array architecture. MESA combines precise electronic beam steering with a compact, solid-state design, delivering high-fidelity radar data without the size, weight, power and cost traditionally associated with high-performance ESA radar. Its architecture supports continuo
AM Green Named Winner of Asian Lot in H2Global Auction Funded by German Government30.9.2026 17:46:00 EEST | Press release
AM Green Ammonia (India) Private Limited ("AM Green") has been selected as the sole winner of the Asian lot in the H2Global auction run by HINT.CO GmbH ("Hintco"), securing a long-term purchase agreement for the supply of Renewable Fuels of Non-Biological Origin (RFNBO) ammonia to Germany. The award follows a competitive bidding process in which AM Green’s offer was ranked first among the submissions received. Over a period of 10 years, Hintco will purchase ammonia from AM Green for a minimum value of EUR 585 million. Hintco may purchase additional quoted volumes from AM Green using proceeds generated from the resale of green ammonia in the European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930707955/en/ Left to right: Timo Bollerhey, CEO of Hintco and Co-Founder of H2Global, and Gautam Reddy, CEO of AM Green Ammonia, mark AM Green’s selection as the sole winner of the Asian lot in the H2Global auction for th
Tangent Robotics Raises 4.5M in Pre-seed Funding to Advance Fine Motor Skills for Robot Dexterity30.9.2026 17:23:00 EEST | Press release
In humans, fine motor skills can take two decades to fully develop. Tangent Robotics, which today announced its pre-seed funding round, aims to speed up the timeline for robots. The company will use the funds to develop skilled robotic manipulation capabilities at the intersection of hand hardware, touch sensing, and motor learning, and deploy them in demanding manufacturing environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930237631/en/ Tangent Robotics is developing fine motor skills for robot hands, which unlock the ability to perform critical tasks for what we want our economy to build locally, fast and at scale "Fine motor skills are hard to learn, and represent a layer that is currently missing in robotics but omnipresent in the real world," says Pedro Piacenza, Tangent's co-founder. "They unlock the ability to perform delicate, intricate manipulation. Tasks like assembly, threading, connector mating, gas
Blue Matter Launches Behavioral Science Center of Excellence to Decode and Predict Health Care Decisions in a Rapidly Evolving Biopharma Landscape30.9.2026 16:00:00 EEST | Press release
Blue Matter today announced the launch of its Behavioral Science Center of Excellence (BeSci CoE), a specialized capability within the Blue Matter Insights primary market research team. The CoE applies behavioral science as a strategic lens to decode the “why” behind the decisions made by healthcare professionals, patients, care partners, and other stakeholders. Biopharma decisions hinge on knowing why customers do what they do. Traditional research does a good job of capturing what stakeholders say but often misses the unconscious drivers, biases, emotions, and contexts that shape behavior. The result is an incomplete picture in the moments where clarity matters most, including when developing positioning strategies, planning product launches, and making major lifecycle decisions. "You don't need a survey to tell you that physicians see efficacy as the most important treatment decision driver," said Andrew Pilecki, Ph.D., Senior Market Research Director at Blue Matter. "What our clien
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
